PlainRecalls
FDA Drug Low Class III Ongoing

Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA, NDC 0904-6592-04.

Reported: April 9, 2025 Initiated: March 4, 2025 #D-0304-2025

Product Description

Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA, NDC 0904-6592-04.

Reason for Recall

Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.

Details

Units Affected
224 cartons
Distribution
Nationwide in the USA
Location
La Vergne, TN

Frequently Asked Questions

What product was recalled?
Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA, NDC 0904-6592-04.. Recalled by The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories. Units affected: 224 cartons.
Why was this product recalled?
Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 9, 2025. Severity: Low. Recall number: D-0304-2025.